Literature DB >> 6323236

Insulin and glucagon regulate cytosolic phosphoenolpyruvate carboxykinase (GTP) mRNA in rat liver.

E Beale, T Andreone, S Koch, M Granner, D Granner.   

Abstract

Insulin causes a 7-10-fold decrease of both the mRNA that codes for rat hepatic phosphoenolpyruvate carboxykinase (mRNAPEPCK) and of PEPCK synthesis, provided the animals are made diabetic and fed chow. mRNAPEPCK, measured either by in vitro translation or cDNA hybridization, decreases with a half-time of 30-60 min after insulin treatment. This coordinant decrease, which approximates the half-life of mRNAPEPCK measured in a variety of situations, suggests that insulin acts by decreasing mRNAPEPCK production, and that the hormone does not alter the activity of a fixed amount of this RNA, or enhance its degradation. Glucagon results in a ninefold induction of mRNAPEPCK. Half-maximal induction occurs with doses between 20-75 micrograms/100 g body wt and occurs within 30-45 min. Maximal induction requires 150 micrograms/100 g body wt and occurs about 80 min after a single glucagon injection. N6,O2'-dibutyryl cAMP and a cAMP analogue that is not metabolized, 8-(4-chlorophenyl-thio)cAMP, induce mRNAPEPCK as effectively as glucagon and with similar kinetics. Since sodium butyrate, adenosine, and dibutyryl cGMP are ineffective inducers, cAMP appears to be the active agent in the hepatocyte.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323236     DOI: 10.2337/diab.33.4.328

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  11 in total

1.  High-resolution two-dimensional polyacrylamide gel electrophoresis reveals a glucose-response protein of 65 kDa in pancreatic islet cells.

Authors:  H W Collins; C Buettger; F Matschinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

Review 2.  Insulin and glucagon signaling in the central nervous system.

Authors:  Beatrice M Filippi; Mona A Abraham; Jessica T Y Yue; Tony K T Lam
Journal:  Rev Endocr Metab Disord       Date:  2013-12       Impact factor: 6.514

3.  Regulation of carnitine palmitoyltransferase in vivo by glucagon and insulin.

Authors:  P S Brady; L J Brady
Journal:  Biochem J       Date:  1989-03-15       Impact factor: 3.857

4.  Excessive glucose production, rather than insulin resistance, accounts for hyperglycaemia in recent-onset streptozotocin-diabetic rats.

Authors:  R Burcelin; M Eddouks; J Maury; J Kande; R Assan; J Girard
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

5.  Rat glucokinase gene: structure and regulation by insulin.

Authors:  M A Magnuson; T L Andreone; R L Printz; S Koch; D K Granner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

6.  Inhibition of gluconeogenesis in isolated rat hepatocytes after chronic treatment with phenobarbital.

Authors:  D Argaud; S Halimi; F Catelloni; X M Leverve
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

7.  Hypothalamic glucagon signaling inhibits hepatic glucose production.

Authors:  Patricia I Mighiu; Jessica T Y Yue; Beatrice M Filippi; Mona A Abraham; Madhu Chari; Carol K L Lam; Clair S Yang; Nikita R Christian; Maureen J Charron; Tony K T Lam
Journal:  Nat Med       Date:  2013-05-19       Impact factor: 53.440

8.  Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyperglycaemia in liver of diabetic rats.

Authors:  R Burcelin; M Eddouks; J Kande; R Assan; J Girard
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

9.  Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice.

Authors:  Young Lee; May-Yun Wang; Xiu Quan Du; Maureen J Charron; Roger H Unger
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

10.  Interaction of Glucagon G-Protein Coupled Receptor with Known Natural Antidiabetic Compounds: Multiscoring In Silico Approach.

Authors:  M H Baig; K Ahmad; Q Hasan; M K A Khan; N S Rao; M A Kamal; I Choi
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-06       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.